/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
The anticoagulant drug, which has an estimated US market size of $447 million, is set to be launched in the first quarter of the 2025-26 fiscal.
Hyderabad-based Aurobindo Pharma announced on Saturday that it has received approval from the United States Food and Drug Administration to manufacture and market its Rivaroxaban 2.5 mg tablets. This drug is the generic equivalent of Janssen Pharmaceuticals’ Xarelto (2.5 mg) and is set to be launched in the first quarter of the 2025-26 fiscal.
Rivaroxaban, an anticoagulant medicine, is used to prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also used in the treatment of deep vein thrombosis and pulmonary embolism. Additionally, it helps prevent deep vein thrombosis in patients undergoing knee or hip replacement …
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
The Hyderabad-based generics maker is now India’s largest supplier of off-patent medicines to the US.
